Communiqués QuidelOrtho Corporation

Actions

QDEL

US2197981051

Equipement et technologie médicale avancés

Temps réel estimé Cboe BZX 18:08:23 21/09/2026			Varia. 5j.	Varia. 1 janv.
10,88 ^USD	+2,45%		-2,16%	-61,90%

06/08	Transcript : QuidelOrtho Corporation, Q2 2026 Earnings Call, Aug 06, 2026
06/08	Flash résultats (QDEL) : QuidelOrtho Corporation publie un chiffre d'affaires de 630,9 millions de dollars au deuxième trimestre, contre 618,7 millions de dollars attendus par le consensus FactSet	MT

Communiqués

06/08	QuidelOrtho: Q2 Earnings Snapshot	AQ
06/08	QuidelOrtho Reports Second Quarter 2026 Financial Results	PR
27/07	QuidelOrtho to Report Second Quarter 2026 Financial Results	AQ
23/07	Beyond Fentanyl: How the Drug Crisis Is Changing	PU
16/07	QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
23/06	QuidelOrtho Appoints Micah Young as Chief Financial Officer	PR
20/05	QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences	PR
06/05	QuidelOrtho : Quarterly Report for Quarter Ending March 29, 2026 (Form 10-Q)	PU
05/05	QuidelOrtho: Q1 Earnings Snapshot	AQ
05/05	QuidelOrtho Reports First Quarter 2026 Financial Results	PR
23/04	QuidelOrtho : Understanding and Addressing Syphilis Trends - and What's Being Missed	PU
20/04	QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics	PR
15/04	QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance	PR
24/03	Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer	PR
19/02	QuidelOrtho : Annual Report for Fiscal Year Ending December 28, 2025 (Form 10-K)	PU
18/02	QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference	PR
11/02	QuidelOrtho: Q4 Earnings Snapshot	AQ
11/02	QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results	PR
03/02	QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards	PR
21/01	QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results	PR
24/11	QuidelOrtho To Participate In Upcoming Investor Conferences	PR
20/11	The Power of Prevention: Detecting Diabetes Before It Strikes	PU
05/11	QuidelOrtho: Q3 Earnings Snapshot	AQ
05/11	QuidelOrtho Reports Third Quarter 2025 Financial Results	PR
03/11	QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay	PR